Grand David, Navrazhina Kristina, Frew John W
Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, United States.
Albert Einstein College of Medicine, Bronx, NY, United States.
Front Med (Lausanne). 2019 Nov 6;6:253. doi: 10.3389/fmed.2019.00253. eCollection 2019.
The development of imaging-based biomarkers has the potential to overcome major challenges in the accurate and reproducible assessment of disease severity and response to novel therapies in Hidradenitis Suppurativa (HS). Understanding the advantages and limitations of existing non-invasive imaging modalities in dermatological disease will aid in the development of hypotheses and inform the design of future studies. A scoping review was performed using Medline, Embase, Web of Science Databases and evaluation of "gray literature" until June 30, 2019. Citations were examined according to pre-defined inclusion and exclusion criteria. Citations were reviewed by two independent reviewers. Narrative Synthesis was used to summarize data, structured by imaging modality. Non-invasive imaging modalities, such as ultrasound, MRI, RCM, EIS, OCT, and MIT, were identified. Only ultrasound, MRI and MIT have been used in HS. Image modalities vary in image depth, resolution, cost, accessibility and correlation with known aspects of disease activity in HS. The benefits and limitations of each imaging modality are products of cost, accessibility, validity and reliability. An additional hurdle to the development of image-based biomarkers in HS is a lack of established analytical benchmarks that can be correlated with existing biological, inflammatory and clinical parameters. This review has identified potential imaging biomarkers, as well as relevant analytical benchmarks that reflect the presence or absence of disease. Further investigation work is needed to analytically and clinically validate these imaging variables in order to identify potential imaging biomarkers in HS.
基于成像的生物标志物的发展有潜力克服化脓性汗腺炎(HS)疾病严重程度准确且可重复评估以及对新疗法反应评估中的重大挑战。了解现有非侵入性成像模式在皮肤病中的优势和局限性将有助于提出假设并为未来研究的设计提供参考。我们使用Medline、Embase、Web of Science数据库以及对“灰色文献”进行评估,开展了一项范围综述,截至2019年6月30日。根据预先定义的纳入和排除标准对文献引用进行审查。由两名独立评审员对文献引用进行评审。采用叙述性综合法按成像模式对数据进行总结。确定了超声、MRI、RCM、EIS、OCT和MIT等非侵入性成像模式。仅超声、MRI和MIT已用于HS。不同成像模式在图像深度、分辨率、成本、可及性以及与HS疾病活动已知方面的相关性方面存在差异。每种成像模式的益处和局限性是成本、可及性、有效性和可靠性的产物。HS中基于成像的生物标志物发展的另一个障碍是缺乏可与现有生物学、炎症和临床参数相关联的既定分析基准。本综述已确定了潜在的成像生物标志物以及反映疾病存在与否的相关分析基准。需要进一步开展研究工作,对这些成像变量进行分析和临床验证,以便在HS中识别潜在的成像生物标志物。